Loading...
•
Jun 30, 2024
Arcellx Q2 2024 Earnings Report
Reported financial results for the second quarter of 2024 and provided business updates.
Key Takeaways
Arcellx reported a $68 million milestone payment from Kite for iMMagine-1 enrollment and the FDA cleared anito-cel IND application for myasthenia gravis. Cash, cash equivalents, and marketable securities totaled $646.8 million. Net losses were $27.2 million.
Earned a $68 million clinical milestone payment from Kite Pharma for iMMagine-1 enrollment.
Submitted an abstract to present data for the iMMagine-1 study at the 66th ASH Annual Meeting and Exposition.
Kite has initiated the global Phase 3 trial, iMMagine-3.
The FDA cleared an IND application for anito-cel for myasthenia gravis.
Forward Guidance
Arcellx anticipates that its cash, cash equivalents, and marketable securities will fund its operations into 2027.
Positive Outlook
- Cash, cash equivalents, and marketable securities will fund its operations into 2027.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...